IP Library › Granted Patent US 8,236,795

Granted Patent B2

US 8,236,795 · App. 12/731,056 · Granted Aug 7, 2012

IL-12 modulatory compounds

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 8,236,795
App. No.: 12/731,056
Granted: Aug 7, 2012
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The invention relates to heterocyclic compounds, compositions including the compounds and methods of using and methods of making thereof. The compounds (and compositions) are useful, inter alia, in modulating IL-12 production and processes mediated by IL-12.

Claims (106)

1. A method for treating an interleukin-12 overproduction-related disorder, comprising administering to a subject in need thereof an effective amount of a compound of formula (I):

or a pharmaceutically acceptable salt thereof,

wherein:

X is represented by a formula selected from the group consisting of:

and

R, for each occurrence, is independently H, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted cyclyl, an optionally substituted heterocycloalkyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, an optionally substituted heteroaralkyl, —C(O)R c , —OR k , —SR k , —NR h R j , hydroxylalkyl, nitro, cyano, haloalkyl, aminoalkyl, or —S(O) 2 R c ;

R 1 is R′-L′-R″;

R′ is an optionally substituted cycloalkyl, an optionally substituted cyclyl, an optionally substituted heterocycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, an optionally substituted heteroaralkyl, or absent;

L′ is O, S(O) p , N(R k ), N(R k )C(O), C(O)N(R k ), C(O)O, or OC(O), or absent; and

R″ is H, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted cyclyl, an optionally substituted heterocycloalkyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, an optionally substituted heteroaralkyl, N(R k )(CH 2 ) n R g , —OR k , —SR k , —NR h R j , hydroxylalkyl, —C(O)R c , —C(S)R c , —C(NR)R c , halo, haloalkyl, aminoalkyl, mercaptoalkyl, cyano, nitro, —S(O)R c , —S(O) 2 R c , —P(O)R c R c , —P(S)R c R c , or an optionally substituted alkylcarbonylalkyl;

Q is CR g , V and U are N;

R 3 is R g , —C(O)R c , —OC(O)R c , —SC(O)R c , —NR k C(O)R c , —C(S)R c , —OC(S)R c , —SC(S)R c , —NR k C(S)R c , —C(NR)R c , —OC(NR)R c , —SC(NR)R c , —NR k C(NR)R c , —S(O) 2 R c , —S(O)R c , —NR k S(O) 2 R c , —OS(O) 2 R c , —OP(O)R c R c , or —P(O)R c R c ;

R 2 and R 4 are, independently, H, an optionally substituted alkyl, an optionally substituted alkylcarbonyl, —OR k , —SR k , —NR h R j , hydroxylalkyl, —C(O)R c , —OC(O)R c , —SC(O)R c , —NR k C(O)R c , —C(S)R c , —OC(S)R c , —SC(S)R c , —NR k C(S)R c , —C(NR)R c , —OC(NR)R c , —SC(NR)R c , —NR k C(NR)R c , —SO 2 R c , —S(O)R c , —NR k SO 2 R c , —OS(O) 2 R c , —OP(O)R c R c , —P(O)R c R c , halo, haloalkyl, aminoalkyl, mercaptoalkyl, cyano, nitro, nitroso, azide, an optionally substituted alkylcarbonylalkyl, an optionally substituted cyclyl, an optionally substituted cycloalkyl, an optionally substituted heterocyclyl, an optionally substituted heterocycloalkyl, an optionally substituted aryl, an optionally substituted aralkyl, an optionally substituted heteroaryl, an optionally substituted heteroaralkyl, or isothionitro; or R 2 and R 4 taken together are ═O, ═S, or ═NR;

R c , for each occurrence, is independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cyclyl, an optionally substituted cycloalkyl, an optionally substituted heterocyclyl, an optionally substituted heterocycloalkyl, an optionally substituted aralkyl, an optionally substituted heteroaralkyl, an optionally substituted aryl, an optionally substituted heteroaryl, haloalkyl, —OR k , —SR k , —NR h R j , hydroxylalkyl, alkylcarbonylalkyl, mercaptoalkyl, aminoalkyl, sulfonylalkyl, sulfonylaryl, or thioalkoxy;

R d and R e , together with the nitrogen to which they are attached, form an optionally substituted heterocycloalkyl, an optionally substituted heterocyclyl, and an optionally substituted heteroaryl;

R g , for each occurrence, is independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cyclyl, an optionally substituted cycloalkyl, an optionally substituted heterocyclyl, an optionally substituted heterocycloalkyl, an optionally substituted aralkyl, an optionally substituted heteroaralkyl, an optionally substituted aryl, an optionally substituted heteroaryl, haloalkyl, —OR k , —SR k , —NR h R j , hydroxylalkyl, alkylcarbonylalkyl, mercaptoalkyl, aminoalkyl, sulfonylalkyl, sulfonylaryl, thioalkoxy, —C(O)R c , —OC(O)R c , —SC(O)R c , —NR k C(O)R c , —C(S)R c , —OC(S)R c , —SC(S)R c , —NR k C(S)R c , —C(NR)R c , —OC(NR)R c , —SC(NR)R c , —NR k C(NR)R c , —S(O) 2 R c , —S(O)R c , —NR k S(O) 2 R c , —OS(O) 2 R c , —OP(O)R c R c , —P(O)R c R c , halo, aminoalkyl, mercaptoalkyl, cyano, nitro, nitroso, or azide;

R h and R j , for each occurrence, are independently H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cyclyl, an optionally substituted cycloalkyl, an optionally substituted heterocyclyl, an optionally substituted heterocycloalkyl, an optionally substituted aralkyl, an optionally substituted heteroaralkyl, an optionally substituted aryl, an optionally substituted heteroaryl; or R h and R j taken together with the N to which they are attached is an optionally substituted heterocyclyl, an optionally substituted heterocycloalkyl, or an optionally substituted heteroaryl;

R k , for each occurrence, is independently H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cyclyl, an optionally substituted cycloalkyl, an optionally substituted heterocyclyl, an optionally substituted heterocycloalkyl, an optionally substituted aralkyl, an optionally substituted heteroaralkyl, an optionally substituted aryl, or an optionally substituted heteroaryl;

G is absent;

Y is O, or CH 2 ;

m is 0, 1, 2, 3, or 4;

n is 0, 1, 2, 3, or 4;

p is 0, 1 or 2;

Z is N; and

W is O;

wherein said interleukin-12 overproduction-related disorder is selected from the group of periodontal disease, osteoporosis, Paget's disease of bone, osteogenesis imperfecta, fibrous dysplasia, primary hyperparathyroidism, estrogen deficiency, inflammatory bone loss, bone malignancy, arthritis, hypercalcemia of malignancy (HCM), osteolytic bone lesions of multiple myeloma, and osteolytic bone metastases of breast cancer.

2. A method for treating an interleukin-12 overproduction-related disorder, comprising administering to a subject in need thereof an effective amount of a compound selected from the group consisting of: 2-Morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidine-4-carboxylic acid (2,3-dimethyl-1H-indol-5-yl)-amide, 2-Morpholin-4-yl-6-(2-pyridin-2-yl-ethoxy)-pyrimidine-4-carboxylic acid (2,3-dimethyl-1H-indol-5-yl)-amide, [6-(2,3-Dimethyl-1H-indol-5-ylcarbamoyl)-2-morpholin-4-yl-pyrimidin-4-yloxy]-acetic acid ethyl ester, 2-Morpholin-4-yl-6-(2-pyridin-2-yl-ethoxy)-pyrimidine-4-carboxylic acid (1H-indol-5-yl)-amide, 2-Morpholin-4-yl-6-(2-pyridin-2-yl-ethoxy)-pyrimidine-4-carboxylic acid m-tolylamide, 6-(2-Hydroxy-2-methyl-propoxy)-2-morpholin-4-yl-pyrimidine-4-carboxylic acid (2,3-dimethyl-1H-indol-5-yl)-amide, 2-Morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidine-4-carboxylic acid (6,7,8,9-tetrahydro-5H-carbazol-3-yl)-amide, 2-Morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidine-4-carboxylic acid (5-furan-2-yl-1H-pyrazol-3-yl)-amide, 1-[2-Morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-3-m-tolyl-urea, 1-[6-(2-Methylamino-ethoxy)-2-morpholin-4-yl-pyrimidin-4-yl]-3-m-tolyl-urea, 1-[6-(2-Hydroxy-2-methyl-propoxy)-2-morpholin-4-yl-pyrimidin-4-yl]-3-m-tolyl-urea, 1-[6-Morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-3-p-tolyl-thiourea, 1-(2-Bromo-4-methyl-phenyl)-3-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-thiourea, 1-[2-Morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-3-phenyl-urea, 1-[2-Morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-3-p-tolyl-urea, 1-(3-Methoxy-phenyl)-3-[2-morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-urea, 1-(4-Chloro-phenyl)-3-[2-morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-urea, 1-(2-Methoxy-phenyl)-3-[2-morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-urea, 1-Benzyl-3-[2-morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-urea, [6-(2,3-Dimethyl-1H-indol-5-ylcarbamoyl)-2-morpholin-4-yl-pyrimidin-4-yloxy]-acetic acid ethyl ester, 2-Morpholin-4-yl-6-[2-(2-oxo-oxazolidin-3-yl)-ethoxy]-pyrimidine-4-carboxylic acid (2,3-dimethyl-1H-indol-5-yl)-amide, 2,6-Di-morpholin-4-yl-pyrimidine-4-carboxylic acid (2,3-dimethyl-1H-indol-5-yl)-amide, 2-Morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidine-4-carboxylic acid (3,4-dimethyl-phenyl)-amide, 2-Morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidine-4-carboxylic acid (1,2,3-trimethyl-1H-indol-5-yl)-amide, 2-Morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidine-4-carboxylic acid (3-carbamoyl-phenyl)-amide, 2-Morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidine-4-carboxylic acid (3-dimethylamino-phenyl)-amide, 2-Morpholin-4-yl-6-[2-(4-oxy-morpholin-4-yl)-ethoxy]-pyrimidine-4-carboxylic acid (2,3-dimethyl-1H-indol-5-yl)-amide, 6-Methoxy-2-morpholin-4-yl-pyrimidine-4-carboxylic acid (2,3-dimethyl-1H-indol-5-yl)-amide, 6-Morpholin-4-yl-4-(2-morpholin-4-yl-ethoxy)-pyridine-2-carboxylic acid (2,3-dimethyl-1H-indol-5-yl)-amide, 4,6-Di-morpholin-4-yl-pyridine-2-carboxylic acid (2,3-dimethyl-1H-indol-5-yl)-amide, 2-Morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidine-4-carboxylic acid methyl-(1,2,3-trimethyl-1H-indol-5-yl)-amide, 2-Morpholin-4-yl-6-(2-pyridin-2-yl-ethoxy)-pyrimidine-4-carboxylic acid (6-methyl-benzothiazol-2-yl)-amide, 2-Morpholin-4-yl-6-(2-pyridin-2-yl-ethoxy)-pyrimidine-4-carboxylic acid (9-ethyl-9H-carbazol-2-yl)-amide, 2-Morpholin-4-yl-6-(2-pyridin-2-yl-ethoxy)-pyrimidine-4-carboxylic acid (6-methyl-pyridin-2-yl)-amide, 2-Morpholin-4-yl-6-(2-pyridin-2-yl-ethoxy)-pyrimidine-4-carboxylic acid (4-methyl-pyridin-2-yl)-amide, 2-Morpholin-4-yl-6-(2-pyridin-2-yl-ethoxy)-pyrimidine-4-carboxylic acid benzothiazol-6-ylamide, 2-Morpholin-4-yl-6-(2-pyridin-2-yl-ethoxy)-pyrimidine-4-carboxylic acid naphthalen-2-ylamide, 2-Morpholin-4-yl-6-(2-pyridin-2-yl-ethoxy)-pyrimidine-4-carboxylic acid quinolin-6-ylamide, 2-Morpholin-4-yl-6-(2-pyridin-2-yl-ethoxy)-pyrimidine-4-carboxylic acid quinolin-5-ylamide, 2-Morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidine-4-carboxylic acid indan-5-ylamide, 2-Morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidine-4-carboxylic acid (2,3-dimethyl-1H-indol-7-yl)-amide, 2-Morpholin-4-yl-6-(2-piperidin-1-yl-ethoxy)-pyrimidine-4-carboxylic acid (2,3-dimethyl-1H-indol-5-yl)-amide, 2-Morpholin-4-yl-6-[2-(2-oxo-oxazolidin-3-yl)-ethoxy]-pyrimidine-4-carboxylic acid (3-carbamoyl-phenyl)-amide, 2-Morpholin-4-yl-6-[2-(2-oxo-oxazolidin-3-yl)-ethoxy]-pyrimidine-4-carboxylic acid m-tolylamide, 2-Morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidine-4-carboxylic acid (5-thiophen-2-yl-1H-pyrazol-3-yl)-amide, 2-Morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidine-4-carboxylic acid (3-ethyl-phenyl)-amide, 2-Morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidine-4-carboxylic acid (3-bromo-phenyl)-amide, 2-Morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidine-4-carboxylic acid (5-methyl-isoxazol-3-yl)-amide, 2-Morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidine-4-carboxylic acid (2-acetylamino-phenyl)-amide, 2-Morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidine-4-carboxylic acid (3-sulfamoyl-phenyl)-amide, 2,6-Di-morpholin-4-yl-pyrimidine-4-carboxylic acid (3,4-dimethyl-phenyl)-amide, 2,6-Di-morpholin-4-yl-pyrimidine-4-carboxylic acid (3-carbamoyl-phenyl)-amide, 2-Morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidine-4-carboxylic acid (3-dimethylcarbamoyl-phenyl)-amide, Indol-1-yl-[2-morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-methanone, (3,4-Dihydro-1H-isoquinolin-2-yl)-[2-morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-methanone, 2-Morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidine-4-carboxylic acid m-tolylamide, 2-Morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidine-4-carboxylic acid (4-dimethylamino-phenyl)-amide, 2-Morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidine-4-carboxylic acid [3-(pyrrolidine-1-carbonyl)-phenyl]-amide, 2-Morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidine-4-carboxylic acid (1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-amide, 2-Morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidine-4-carboxylic acid (2-methoxy-5-methyl-phenyl)-amide, 2-Morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-pyrimidine-4-carboxylic acid (3-hydroxy-phenyl)-amide, 6-Morpholin-4-yl-2-(2-pyridin-2-yl-ethoxy)-pyrimidine-4-carboxylic acid m-tolylamide, 6-Morpholin-4-yl-2-(2-pyridin-2-yl-ethoxy)-pyrimidine-4-carboxylic acid (2,3-dimethyl-1H-indol-5-yl)-amide, 6-Morpholin-4-yl-2-(2-pyridin-2-yl-ethoxy)-pyrimidine-4-carboxylic acid (6-methyl-benzothiazol-2-yl)-amide, 2-[2-(3,4-Dimethoxy-phenyl)-ethoxy]-6-morpholin-4-yl-N-m-tolyl-isonicotinamide, N-(2,3-Dimethyl-1H-indol-5-yl)-2-morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-isonicotinamide, 1-[2-Morpholin-4-yl-6-(2-pyridin-2-yl-ethoxy)-pyrimidin-4-yl]-3-m-tolyl-urea, 1-[6-Morpholin-4-yl-2-(2-pyridin-2-yl-ethoxy)-pyrimidin-4-yl]-3-m-tolyl-urea, 1-Methyl-3-[6-morpholin-4-yl-2-(2-pyridin-2-yl-ethoxy)-pyrimidin-4-yl]-1-m-tolyl-urea, 1-(4,6-Di-morpholin-4-yl-pyridin-2-yl)-3-m-tolyl-urea, 1-[4-Morpholin-4-yl-6-(2-pyridin-2-yl-ethoxy)-pyrimidin-2-yl]-3-m-tolyl-urea, 2-Morpholin-4-yl-6-(2-pyridin-2-yl-ethoxy)-pyrimidine-4-carboxylic acid 1H-indol-5-yl ester, 1H-Indole-5-carboxylic acid [2-morpholin-4-yl-6-(2-pyridin-2-yl-ethoxy)-pyrimidin-4-yl]-amide, 1H-Indole-5-carboxylic acid [6-morpholin-4-yl-2-(2-pyridin-2-yl-ethoxy)-pyrimidin-4-yl]-amide, 3-Methyl-N-[4-morpholin-4-yl-6-(2-pyridin-2-yl-ethoxy)-pyrimidin-2-yl]-benzamide, N-[4-Morpholin-4-yl-6-(2-pyridin-2-yl-ethoxy)-pyrimidin-2-yl]-isonicotinamide, 5-Methyl-isoxazole-3-carboxylic acid-p-morpholin-4-yl-6-(2-pyridin-2-yl-ethoxy)-pyrimidin-2-yl]-amide, 6-Morpholin-4-yl-2-(2-pyridin-2-yl-ethoxy)-pyrimidine-4-carboxylic acid N′-m-tolyl-hydrazide, 2-Morpholin-4-yl-6-(2-pyridin-2-yl-ethoxy)-pyrimidine-4-carboxylic acid N′-m-tolyl-hydrazide, 6-Morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidine-4-carboxylic acid N′-m-tolyl-hydrazide, 6-Morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidine-4-carboxylic acid N′-(3,4-dimethyl-phenyl)-hydrazide, 2-Morpholin-4-yl-6-(2-morpholin-4-yl-ethoxy)-isonicotinic acid N′-m-tolyl-hydrazide, [2-Morpholin-4-yl-6-(2-pyridin-2-yl-ethoxy)-pyrimidin-4-yl]-carbamic acid m-tolyl ester, (2,3-Dimethyl-1H-indol-5-yl)-[2-morpholin-4-yl-6-(2-pyridin-2-yl-ethoxy)-pyrimidin-4-ylmethyl]-amine, N-[2-Morpholin-4-yl-6-(2-pyridin-2-yl-ethoxy)-pyrimidin-4-yl]-N′-m-tolyl-oxalamide, N-(3-Hydroxy-phenyl)-N′-[2-morpholin-4-yl-6-(2-pyridin-2-yl-ethoxy)-pyrimidin-4-yl]-oxalamide, N-(3-Hydroxy-phenyl)-N′-[6-morpholin-4-yl-2-(2-pyridin-2-yl-ethoxy)-pyrimidin-4-yl]-oxalamide, and [6-Morpholin-4-yl-2-(2-pyridin-2-yl-ethoxy)-pyrimidin-4-yl]-carbamic acid m-tolyl ester, or a pharmaceutically acceptable salt thereof,

3. A method for treating disorders associated with excessive bone loss, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I):

or a pharmaceutically acceptable salt thereof,

wherein:

X is represented by a formula selected from the group consisting of:

and

R 1 is R′-L′-R″;

L′ is O, S(O) p , N(R k ), N(R k )C(O), C(O)N(R k ), C(O)O, or OC(O), or absent; and

Q is CR g , V and U are N;

R d and R e , together with the nitrogen to which they are attached, form an optionally substituted heterocycloalkyl, an optionally substituted heterocyclyl, and an optionally substituted heteroaryl;

G is absent;

Y is O, or CH 2 ;

m is 0, 1, 2, 3, or 4;

n is 0, 1, 2, 3, or 4;

p is 0, 1 or 2;

Z is N; and

W is O,

wherein said disorder is selected from the group of periodontal disease, osteoporosis, Paget's disease of bone, osteogenesis imperfecta, fibrous dysplasia, primary hyperparathyroidism, estrogen deficiency, inflammatory bone loss, bone malignancy, arthritis, hypercalcemia of malignancy (HCM), osteolytic bone lesions of multiple myeloma, and osteolytic bone metastases of breast cancer.

4. A method of treating a disorder associated with excessive bone resorption by osteoclasts in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of formula (I):

or a pharmaceutically acceptable salt thereof,

wherein:

X is represented by a formula selected from the group consisting of:

and

R 1 is R′-L′-R″;

L′ is O, S(O) p , N(R k ), N(R k )C(O), C(O)N(R k ), C(O)O, or OC(O), or absent; and

Q is CR g , V and U are N;

R d and R e , together with the nitrogen to which they are attached, form an optionally substituted heterocycloalkyl, an optionally substituted heterocyclyl, and an optionally substituted heteroaryl;

G is absent;

Y is O, or CH 2 ;

m is 0, 1, 2, 3, or 4;

n is 0, 1, 2, 3, or 4;

p is 0, 1 or 2;

Z is N; and

W is O,

5. A method of inhibiting IL-23 and/or IL-27 production in a subject, comprising administering to the subject an effective amount of a compound of formula (I):

or a pharmaceutically acceptable salt thereof,

wherein:

X is represented by a formula selected from the group consisting of:

and

R 1 is R′-L′-R″;

L′ is O, S(O) p , N(R k ), N(R k )C(O), C(O)N(R k ), C(O)O, or OC(O), or absent; and

Q is CR g , V and U are N;

R d and R e , together with the nitrogen to which they are attached, form an optionally substituted heterocycloalkyl, an optionally substituted heterocyclyl, and an optionally substituted heteroaryl;

G is absent;

Y is O, or CH 2 ;

m is 0, 1, 2, 3, or 4;

n is 0, 1, 2, 3, or 4;

p is 0, 1 or 2;

Z is N; and

W is O.

6. The method of claim 5 , further comprising inhibiting the production of IL-12.

Assignments (4)

SECURITY INTEREST Recorded Feb 18, 2026

From: ORPHAI THERAPEUTICS INC.

To: ACADIA WOODS PARTNERS, LLC, AS AGENT